Position in URGN
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$30,088,091
-$3,833,905 QoQ
Shares Held
1,673,420
+15.5% QoQ
Ownership
3.43%
of shares outstanding
% of Portfolio
8.58%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2024
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in URGN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026ACORN CAPITAL ADVISORS, LLC holds $350,733,296 across 21 Biotechnology names. URGN ranks #3 (8.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TERN |
Terns Pharmaceuticals, Inc.
|
1,746,264 | $92,063,038 | |
| 2 | CGON |
CG Oncology, Inc.
|
1,130,501 | $76,512,307 | |
| 3 | URGN |
UroGen Pharma Ltd.
This page
|
1,673,420 | $30,088,091 | |
| 4 | PBYI |
Puma Biotechnology, Inc.
|
4,131,299 | $26,399,000 | |
| 5 | TRVI |
Trevi Therapeutics, Inc.
|
2,144,844 | $25,587,988 | |
| 6 | CADL |
Candel Therapeutics, Inc.
|
3,497,948 | $17,139,945 | |
| 7 | BCAX |
Bicara Therapeutics Inc.
|
643,382 | $12,796,867 | |
| 8 | OKUR |
OnKure Therapeutics, Inc.
|
2,839,674 | $11,756,250 |
All Filings in URGN
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $30,088,091 | 1,673,420 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $33,921,996 | 1,448,420 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $25,131,992 | 1,259,749 | Shares | Sole | 2025-11-17 | |
| 2025-06-30 | $17,258,561 | 1,259,749 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $16,770,311 | 1,516,303 | Shares | Sole | 2025-05-19 | |
| 2024-12-31 | $16,148,626 | 1,516,303 | Shares | Sole | 2025-05-19 | |
| No filing history on record for this holder in this stock. | ||||||